IPO Details
Bidding Dates
14 May 25 - 16 May 25
Lot Size
1200
Price Range ₹
96 - 101
Exchange Status
NSE
Total Equity
₹ 30.30Cr
IPO Doc
IPO Timeline
Listing
--
Offer start
14 May 2025
Offer end
16 May 2025
Allotment
19 May 2025
Refund initiation
20 May 2025
Demat transfer
20 May 2025
Listing
--
Offer start
14 May 2025
Offer end
16 May 2025
Allotment
19 May 2025
Refund initiation
20 May 2025
Demat transfer
20 May 2025
About Company
Accretion Pharmaceuticals Limited, incorporated in 2012, is a Gujarat-based pharmaceutical company engaged in the manufacturing and marketing of a diverse range of healthcare products including tablets, capsules, syrups, external preparations, and ayurvedic formulations. The company also provides contract manufacturing services and operates a certified manufacturing facility in Sanand, Ahmedabad. With ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 accreditations, it ensures adherence to quality and environmental standards. Accretion has successfully expanded its global presence to over 20 countries across Africa, Southeast Asia, and the Middle East, supported by an experienced management team and a workforce of 83 employees.
Year Founded
29-11-2023
Promotor Details
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
| Percentage | 100 | 0 |
| Share Capital | 8170000 | 8170000 |
Offer to Public
30,00,000.00 Cr
Project Details
- Repayment/prepayment of certain borrowings availed by our Company - 16.006cr
- Capital expenditure towards purchase of new equipment/ machineries, etc. - 26.973cr
- Repayment/prepayment of certain borrowings availed by our Company - 15.982cr
- Capital expenditure towards upgradation of existing manufacturing facility - 46.557cr
Objectives
- a.Capital expenditure towards purchase of new equipment/machineries, etc.b.Capital expenditure towards upgradation of existing manufacturing facility
- c.Repayment/prepayment of certain borrowings availed by our Company
- d.Funding working capital requirements
- ande.General Corporate Purpose
Highlights
- Incorporated in 2012 with over a decade of experience in pharmaceutical manufacturing and marketing.
- Diverse product portfolio including tablets, capsules, oral liquids, external applications, and ayurvedic products.
- Holds ISO 9001:2015, 14001:2015, and 22000:2005 certifications, ensuring quality and compliance.
- Strong international presence with exports to over 20 countries across Africa, Southeast Asia, and the Middle East.
- Experienced promoters and long-standing relationships with clients and suppliers that foster business stability.
Challenges
- Operates from a single manufacturing facility, leading to potential capacity and geographic risk.
- Relatively small employee base (83 staff) may limit rapid scalability or expansion into regulated markets.
- Intense competition in the pharmaceutical sector, especially in generic and contract manufacturing.
- Regulatory risks and compliance requirements across multiple countries can impact exports.
- Dependence on international markets exposes the company to forex fluctuations and geopolitical uncertainties.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
| 2024 | 2,704.61 | 400.00 | 387.53 | 387.53 | 5.0991 |
